Vitality Watch

Dossier pubmed review 14-nov-2026
Narrative review or expert overview without new data

Immunosenescence and vaccine adjuvants in older adults: from immune decline to signal reconstitution strategies.

Key claim: Overcoming impaired vaccine responsiveness in older adults requires targeted adjuvant strategies that reconstitute or bypass age-associated immune signaling deficits rather than relying on antigen optimization alone.

Abstract

Immunosenescence is characterized by progressive deterioration of innate and adaptive immune function, resulting in reduced vaccine efficacy, durability, and immune quality in older adults. Age-associated alterations include impaired dendritic cell activation, reduced type I interferon production, diminished naïve T-cell output, defective T follicular helper cell differentiation, weakened germinal center responses, and chronic low-grade inflammation. Consequently, vaccine responsiveness in older adults is often limited by defects in immune signaling and coordination that cannot be fully overcome by antigen optimization alone. In this review, we examine the biological basis of immunosenescence and discuss how vaccine adjuvants can improve immune responses in aging populations. We propose a conceptual framework in which adjuvants act through three non-mutually exclusive mechanisms: signal amplification, signal reconstitution, and functional bypass. Using this framework, we evaluate licensed adjuvants currently used in older adults, including AS01, MF59, AS03, and CpG1018, and discuss emerging adjuvant platforms under development. Collectively, current evidence suggests that effective vaccination in older adults requires strategies that address age-associated immune dysfunction in addition to antigen delivery. A better understanding of immunosenescence and adjuvant biology may facilitate the development of precision vaccination approaches tailored to specific immune deficits in aging populations.

Why this matters

[expert-opinion] This review frames impaired vaccine responsiveness as a problem of specific age-associated signaling deficits, organizing adjuvant approaches by whether they amplify residual signals, reconstitute deficient signals, or bypass impaired functions. [expert-opinion] The framework connects immune-aging biology to vaccine design, but does not itself establish which strategy provides superior clinical protection in older adults or equate improved vaccine responsiveness with broader immune rejuvenation.

Source

Link

Briefing card

Immunosenescence and vaccine adjuvants in older adults: from immune decline to signal reconstitution strategies.
Stage: review · pubmed · 14-nov-2026

Overcoming impaired vaccine responsiveness in older adults requires targeted adjuvant strategies that reconstitute or bypass age-associated immune signaling deficits rather than relying on antigen optimization alone.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.vaccine.2026.129348

build build 880 · 2bcef25 · 2026-11-18